Johnson & Johnson

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-04-17 pm EDT After market 07:01:27 pm
144.8 USD +0.22% Intraday chart for Johnson & Johnson 144.5 -0.19%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Johnson & Johnson's Q1 Had 'Some Puts and Takes,' Morgan Stanley Says MT
BofA Securities Adjusts Price Target on Johnson & Johnson to $170 From $180, Maintains Neutral Rating MT
Morgan Stanley Adjusts Johnson & Johnson's Price Target to $167 From $168, Keeps Equalweight Rating MT
RBC Adjusts Johnson & Johnson's Price Target to $175 From $181, Keeps Outperform Rating MT
Raymond James Adjusts Johnson & Johnson's Price Target to $170 From $175, Maintains Outperform Rating MT
Sector Update: Health Care Stocks Higher Late Afternoon MT
Stifel Cuts Johnson & Johnson's Price Target to $155 From $160 MT
US stocks see-saw as rising Treasury yields, Middle East tensions cap gains RE
Recursion Pharmaceuticals Names Najat Khan Chief R&D Officer MT
Wall Street stocks mixed on higher Treasury yields, rate expectations RE
Sector Update: Health Care Stocks Edge Up Tuesday Afternoon MT
Correction to Johnson & Johnson Earnings Article DJ
Top Midday Stories: UnitedHealth, Johnson & Johnson, Bank of America, Morgan Stanley, PNC, Bank of New York Mellon, Northern Trust and Ericsson Report Q1 Earnings; AMD Launches New Processors; Meta's Zuckerberg Wins Case Dismissal; Planet Fitness Names New CEO MT
S&P, Nasdaq muted as bond yields rise; UnitedHealth boosts Dow RE
Trending : Johnson & Johnson 1Q Adjust Earnings Beat Forecasts as Company Raises Dividend DJ
Sector Update: Health Care Stocks Mixed Premarket Tuesday MT
Market sentiment sours Our Logo
Johnson & Johnson Narrows Full-Year Outlook as First-Quarter Sales Miss Street Views MT
Wall St set for higher open as upbeat earnings obscure Mideast jitters RE
Transcript : Johnson & Johnson, Q1 2024 Earnings Call, Apr 16, 2024
Johnson & Johnson: EPS up to $2.20 in Q1 CF
Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug MT
Fed Outlook, Overseas Markets Cap Wall Street Pre-Bell; Asia, Europe Lower MT
Stock Futures Decline Pre-Bell as Traders Await More Earnings; Asia, Europe Down MT
Johnson & Johnson's Q1 Adjusted Earnings, Revenue Increase; 2024 Guidance Narrowed; Quarterly Dividend Lifted MT
Chart Johnson & Johnson
More charts
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
144.8 USD
Average target price
172.5 USD
Spread / Average Target
+19.14%
Consensus